Comparison between monotherapy and combination therapy among inpatients with community-acquired pneumonia
Abstract
Background: Pneumonia causes high mortality, hospitalization costs and health services. There is some growing debate regarding the efficacy of different treatment management approaches. The use of certain antibiotic regimens combination and monotherapy have been associated with improved outcomes. Objective: This study aims to determine the effectiveness of monotherapy and combination therapy on length of stay. Method: This retrospective study included patients with Community Acquired Pneumonia (CAP) who received empirical therapy between January - December 2017 at Jakarta Islamic Hospital of Cempaka Putih. Two hundred and ninety four subjects were included in this study. Results: Subjects who received monotherapy and combination therapy were 73.8% and 26.2%. Mean length of stay was 5 days. The most widely used antibiotic in this study was ceftriaxone with levofloxacin (35%) for combination therapy and levofloxacin (38,2%) for monotherapy. There is a relationship between comorbidities and long-term hospitalization (p=0.008). Conclusion: There was no significant difference between combination therapy and monotherapy with length of stay (p=0.277). Keywords: Pneumonia, monotherapy, combination therapy, Jakarta Islamic Hospital of Cempaka Putih
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.